Denial recovery
Clean documentation at the point of order converts would-be denials to clean pays. 86% of imaging denials are potentially avoidable[1].
ROI narrative
Here's the money — conservatively. Modeled for a regional hospital group at 120,000 advanced-imaging orders a year, gross recovery lands near $4.12M/yr[1][3][6]. Your inputs will differ — run your own numbers.
ARKA helps hospital systems turn avoidable advanced-imaging denials into clean, paid claims — cutting denial write-offs on their highest-margin service line by up to 30–40% by documenting medical necessity at the point of order and running the same appropriateness check on the payer side — recovering ~$3.5M/yr for a mid-sized system, without adding headcount.
Modeled, conservative estimate. ARKA is Non-Device CDS — figures are decision-support economics, not a guarantee of outcomes. Aggressive case ≈ 1.5× the conservative figures.
Each lever below is a conservative, sourced estimate. ARKA is Non-Device CDS — the ordering clinician retains full responsibility for the final decision.
Clean documentation at the point of order converts would-be denials to clean pays. 86% of imaging denials are potentially avoidable[1].
Administrative cost to rework a denied claim runs $25–$118 fully loaded; MGMA estimates 50–65% of denials are never reworked[3].
Faster prior-auth approvals shorten the backlog on your highest-margin imaging line — modeled at $500K/yr at baseline volume[6].
When documentation is complete at order entry, clean orders clear payer review without a queue — 35–40% of orders auto-clear[4].
CMS-0057-F requires a specific denial reason enforced through 2026 and four FHIR APIs (including Da Vinci PAS) by January 1, 2027. CMS-0057-F compliance matrix.
20,000 advanced-imaging orders per year · 20% initial denial rate · blended reimbursement $1K[6].
Modeled — your inputs will differ. Figures use the same conservative assumptions as the interactive ROI calculator; every assumption, its source, and its provenance are documented in the ROI methodology.
Value at risk Modeled | Modeled gross recovery / yr Modeled | Payback <6 months[1] Modeled | Year-1 net Modeled |
At-risk revenue reflects permanently lost avoidable denials (never reworked). Gross recovery includes denial conversion, rework labor avoided, and throughput defense — subscription cost deducted for Year-1 net. Assumes 2.5% of all studies converted to clean pays and a ~2.3× first-year return multiple.
Modeled economics get you to a business case. Measured outcomes get you to a contract. We align on KPIs before go-live — denial-rate trend, PA turnaround within CMS-0057-F SLAs, appropriateness score distribution, and rework hours avoided — using the framework in our Outcomes & KPI guide.
ROI narrative
Here's the money — conservatively. Modeled for a regional hospital group at 120,000 advanced-imaging orders a year, gross recovery lands near $4.12M/yr[1][3][6]. Your inputs will differ — run your own numbers.
ARKA helps hospital systems turn avoidable advanced-imaging denials into clean, paid claims — cutting denial write-offs on their highest-margin service line by up to 30–40% by documenting medical necessity at the point of order and running the same appropriateness check on the payer side — recovering ~$3.5M/yr for a mid-sized system, without adding headcount.
Modeled, conservative estimate. ARKA is Non-Device CDS — figures are decision-support economics, not a guarantee of outcomes. Aggressive case ≈ 1.5× the conservative figures.
Each lever below is a conservative, sourced estimate. ARKA is Non-Device CDS — the ordering clinician retains full responsibility for the final decision.
Clean documentation at the point of order converts would-be denials to clean pays. 86% of imaging denials are potentially avoidable[1].
Administrative cost to rework a denied claim runs $25–$118 fully loaded; MGMA estimates 50–65% of denials are never reworked[3].
Faster prior-auth approvals shorten the backlog on your highest-margin imaging line — modeled at $500K/yr at baseline volume[6].
When documentation is complete at order entry, clean orders clear payer review without a queue — 35–40% of orders auto-clear[4].
CMS-0057-F requires a specific denial reason enforced through 2026 and four FHIR APIs (including Da Vinci PAS) by January 1, 2027. CMS-0057-F compliance matrix.
20,000 advanced-imaging orders per year · 20% initial denial rate · blended reimbursement $1K[6].
Modeled — your inputs will differ. Figures use the same conservative assumptions as the interactive ROI calculator; every assumption, its source, and its provenance are documented in the ROI methodology.
Value at risk Modeled | Modeled gross recovery / yr Modeled | Payback <6 months[1] Modeled | Year-1 net Modeled |
At-risk revenue reflects permanently lost avoidable denials (never reworked). Gross recovery includes denial conversion, rework labor avoided, and throughput defense — subscription cost deducted for Year-1 net. Assumes 2.5% of all studies converted to clean pays and a ~2.3× first-year return multiple.
Modeled economics get you to a business case. Measured outcomes get you to a contract. We align on KPIs before go-live — denial-rate trend, PA turnaround within CMS-0057-F SLAs, appropriateness score distribution, and rework hours avoided — using the framework in our Outcomes & KPI guide.